 Long-term transfusion therapy, a supporting treatment for patients with intractable chronic anemia is currently the most frequent cause of secondary iron overload. Both Aplastic anemia AA and low risk low and intermediate-1 risk myelodysplastic syndromes MDS are classified into bone marrow failure syndromes BMFs as they have a lot of characters in common. Iron overload IOL can then become a significant problem in regularly transfused patients, leading to organ damage, particularly in the liver and heart. Iron overload also has a suppressive effect on erythroid progenitors and may increase transfusion requirements. In those cases, iron chelation therapy may help to improve their quality of life and prolong their survival. 